BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38339173)

  • 1. The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype?
    Chiloiro S; Capoluongo ED; Costanza F; Minucci A; Giampietro A; Infante A; Milardi D; Ricciardi Tenore C; De Bonis M; Gaudino S; Rindi G; Olivi A; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
    Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coincidence of multiple endocrine neoplasia type 2A with acromegaly.
    Saito T; Miura D; Taguchi M; Takeshita A; Miyakawa M; Takeuchi Y
    Am J Med Sci; 2010 Oct; 340(4):329-31. PubMed ID: 20739875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.
    Yang Z; Qi X; Gross N; Kou X; Bai Y; Feng Y; Wang B; Zafereo ME; Li G; Sun C; Li H; Chen X; Huang Z
    J Cell Mol Med; 2020 Nov; 24(22):13163-13170. PubMed ID: 32989896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protean role of Val804Met RET mutation in thyroid neoplasms: An example of a "MEN2C" syndrome?
    Miani C; Locatello LG; Rugiu MG; Antonio JK; Di Loreto C; Pegolo E
    Pathol Res Pract; 2023 Apr; 244():154388. PubMed ID: 36889173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.
    Wagner SM; Zhu S; Nicolescu AC; Mulligan LM
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):77-84. PubMed ID: 22584710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
    Romei C; Mariotti S; Fugazzola L; Taccaliti A; Pacini F; Opocher G; Mian C; Castellano M; degli Uberti E; Ceccherini I; Cremonini N; Seregni E; Orlandi F; Ferolla P; Puxeddu E; Giorgino F; Colao A; Loli P; Bondi F; Cosci B; Bottici V; Cappai A; Pinna G; Persani L; Verga U; Boscaro M; Castagna MG; Cappelli C; Zatelli MC; Faggiano A; Francia G; Brandi ML; Falchetti A; Pinchera A; Elisei R;
    Eur J Endocrinol; 2010 Aug; 163(2):301-8. PubMed ID: 20516206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-specific progression of hereditary medullary thyroid cancer.
    Machens A; Lorenz K; Weber F; Dralle H
    Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET codon 609 mutations: a contribution for better clinical managing.
    Mian C; Sartorato P; Barollo S; Zane M; Opocher G
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.
    Elisei R; Tacito A; Ramone T; Ciampi R; Bottici V; Cappagli V; Viola D; Matrone A; Lorusso L; Valerio L; Giani C; Campopiano C; Prete A; Agate L; Molinaro E; Romei C
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31510104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.
    Valente FO; Dias da Silva MR; Camacho CP; Kunii IS; Bastos AU; da Fonseca CC; Simião HP; Tamanaha R; Maciel RM; Cerutti JM
    J Endocrinol Invest; 2013 Dec; 36(11):975-81. PubMed ID: 23723040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare RET Variant p.D707E in a Chinese Pedigree with Hereditary Medullary Thyroid Carcinoma.
    Zhang L; Li X; Li Q; Ge S; Chen M; Huang S; Chen B; Li P; Teng B; Xu J; Zhao S; Qi F; Zhang Y
    Pathobiology; 2017; 84(3):152-160. PubMed ID: 27798940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.
    Silva AL; Carmo F; Moura MM; Domingues R; Espadinha C; Leite V; Cavaco B; Bugalho MJ
    Endocrine; 2015 Jun; 49(2):366-72. PubMed ID: 25725622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome.
    Alegría-Landa V; Jo-Velasco M; Robledo M; Requena L
    JAMA Dermatol; 2017 Dec; 153(12):1298-1301. PubMed ID: 29049491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family.
    Qi XP; Ma JM; Du ZF; Ying RB; Fei J; Jin HY; Han JS; Wang JQ; Chen XL; Chen CY; Liu WT; Lu JJ; Zhang JG; Zhang XN
    PLoS One; 2011; 6(5):e20353. PubMed ID: 21655256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.
    Loveday C; Josephs K; Chubb D; Gunning A; Izatt L; Tischkowitz M; Ellard S; Turnbull C
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4275-4282. PubMed ID: 29590403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.